Allogene Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 6, 2026, disclosing a net loss of $50.369 million for the three months ended September 30, 2026.

Key Highlights

  • Net loss of $50.369 million for the three months ended September 30, 2026, compared to a net loss of $41.400 million in the same period of 2025, according to the filing.
  • Nine-month net loss of $135.653 million for the period ended September 30, 2026, versus $152.076 million for the same period in 2025.
  • Shares outstanding rose to 346,279,825 as of September 30, 2026, up from 229,413,523 as of December 31, 2025, reflecting a public offering and ATM issuances.
  • Public offering raised approximately $187.872 million net of commissions and offering costs of $12.5 million, with 100,200,000 shares issued in Q2 2026.
  • Total assets of $511.320 million as of September 30, 2026, compared to $415.905 million as of December 31, 2025.
  • Collaboration revenue of $4.640 million from a related party was recorded for the nine months ended September 30, 2026, with no such revenue in the comparable 2025 period.
  • Accumulated deficit reached $2.146 billion as of September 30, 2026, up from $2.011 billion at December 31, 2025.

Allogene Therapeutics Financial Results for the Quarter and Nine Months Ended September 30, 2026

According to the filing, Allogene Therapeutics (NASDAQ:ALLO) reported a net loss of $50.369 million for the three months ended September 30, 2026, compared to a net loss of $41.400 million for the same quarter in 2025. The net loss per share, basic and diluted, was $(0.15) for the third quarter of 2026, based on a weighted-average share count of 346,092,814, versus $(0.19) per share on 222,038,680 weighted-average shares in the third quarter of 2025.

The filing disclosed total operating expenses of $54.793 million for the third quarter of 2026, driven by research and development expenses of $41.934 million and general and administrative expenses of $12.859 million. For the nine months ended September 30, 2026, the company reported total operating expenses of $152.445 million, with research and development expenses of $104.658 million and general and administrative expenses of $47.787 million. The company recorded no collaboration revenue for the third quarter of 2026, though $4.640 million in collaboration revenue from a related party was recognized in the first nine months of 2026.

On the balance sheet, the company reported total assets of $511.320 million as of September 30, 2026, compared to $415.905 million at December 31, 2025. Cash and cash equivalents stood at $29.270 million, while short-term investments totaled $263.688 million and long-term investments were $95.915 million. Total stockholders' equity was $392.552 million as of September 30, 2026. The company disclosed that shares authorized under common stock increased from 400,000,000 to 800,000,000 between December 31, 2025 and September 30, 2026. As of November 3, 2026, the registrant reported 346,467,307 shares of common stock outstanding.

What Was Disclosed

Allogene Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, reporting a net loss of $50.369 million for the quarter, an accumulated deficit of $2.146 billion, and a significant increase in shares outstanding following equity offerings completed during the nine-month period.